Merck announces over €300m investment in new bioprocessing center in South Korea
Merck has embarked on a monumental investment venture, injecting more than €300 million into the construction of a new Bioprocessing Production Center located in Daejeon, ... Read More
Merck’s KEYTRUDA shows 38% reduction in death risk for renal cell carcinoma patients in Phase 3 KEYNOTE-564 trial
Merck & Co., Inc., a global healthcare leader, has recently unveiled groundbreaking results from its Phase 3 KEYNOTE-564 trial. This pivotal study demonstrates that KEYTRUDA, ... Read More
FDA approves Merck’s KEYTRUDA for advanced cervical cancer treatment
Merck, known as MSD outside of the United States and Canada, has received approval from the U.S. Food and Drug Administration (FDA) for KEYTRUDA, its ... Read More
Merck to acquire Harpoon Therapeutics for $680m to strengthen oncology pipeline
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Harpoon Therapeutics, Inc. (Nasdaq: HARP) have entered a definitive agreement where Merck ... Read More
Merck, Inspirna join forces to develop first-in-class oral cancer inhibitor
Merck, a renowned science and technology company, has reached a significant milestone in its efforts to combat cancer. The company announced a strategic licensing agreement ... Read More
Moderna, Merck announce promising results for mRNA-4157 and Keytruda in melanoma
Moderna, Inc. (NASDAQ: MRNA) and Merck (NYSE: MRK), also known as MSD outside the United States and Canada, today revealed follow-up data from their collaborative ... Read More
Merck to acquire Caraway Therapeutics in $610m deal for neurodegenerative disease treatments
Merck and Caraway Therapeutics, Inc. have announced a definitive agreement in which Merck, through a subsidiary, will acquire Caraway Therapeutics. The total potential consideration for ... Read More
Merck strikes €1.4bn deal with Hengrui Pharmaceuticals for next-gen oncology treatments
In a major advancement in cancer treatment, Merck, a frontrunner in science and technology, has declared a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. ... Read More
Merck launches Phase 3 CORALreef program for PCSK9 inhibitor MK-0616
Pharmaceutical giant Merck has announced the initiation of its groundbreaking Phase 3 clinical program, CORALreef, focusing on MK-0616—a novel, oral proprotein convertase subtilisin/kexin type 9 ... Read More
Merck’s WELIREG meets primary endpoint of PFS in Phase 3 RCC trial
Global pharmaceutical leader Merck has announced that WELIREG (belzutifan), its pioneering oral HIF-2α inhibitor, has achieved a critical milestone in its Phase 3 trial LITESPARK-005. ... Read More